Recently, eagle-eyed netizens have spotted that OpenAI's API pricing page has discreetly listed a new life sciences model, gpt-rosalind-discovery, which has yet to be officially announced. This model shares identical pricing with the publicly accessible gpt-rosalind-research, fueling conjecture that it may be tailored specifically for the drug discovery sector. Currently, OpenAI has forged an independent life sciences brand, Rosalind, and has paved the way for delivering multiple product categories. Previously, OpenAI has partnered with several pharmaceutical companies to delve into the application of AI in drug development and has initiated a biodefense program. As the first prominent general large model provider to carve out an independent brand, establish independent access reviews, and iterate model versions for the life sciences domain, OpenAI is positioning itself as a tool supplier. It plans to sell specialized models exclusively to approved institutions, steering clear of direct involvement in drug development pipelines.

The life sciences field is distinguished by its high added value, robust payment capacity, and well-defined pain points. Presently, OpenAI is employing a strategy akin to "parity pricing" (Note: The term "At Par" has been contextualized as "parity pricing" to better reflect the strategy of offering competitive and accessible pricing, though "affordable" could also be fitting depending on the intended nuance) to lure leading pharmaceutical companies and research institutions, with the aim of amassing scenario-based experience. However, the application of AI in the biological realm (AI4Bio) still lacks extensive clinical validation, with models primarily functioning to streamline manual labor.

OpenAI is striving to achieve swift monetization in the life sciences arena by segmenting different model versions according to task. Nevertheless, at this juncture, the specific differential positioning of the two models sharing the same price, the practical applications of the new model, and the advantages it confers remain ambiguous. Its subsequent deployment will necessitate pertinent evaluations and empirical evidence for backing.